21 days ago
Brooke Eby, the TikTok star known for sharing her journey with ALS (or Lou Gehrig's disease), has passed away at the age of 37. Eby was diagnosed with the illness in March 2022, though her symptoms started four years prior, and she began posting videos on TikTok just months after. She soon gained hundreds of thousands of fans on TikTok and Instagram.
The ALS Network shared the news of Eby's death on October 1st, with a statement remembering her for the ways she built community and helped create connections through her videos and other work.
Per reporting by People, Sheri Strahl, President and CEO of ALS Network, said of Eby: "Brooke changed the way people see ALS, but she also changed the way people living with ALS find and support one another[…] Brooke changed the way people see ALS, but she also changed the way people living with ALS find and support one another."
Brooke did that by approaching ALS in a comedic and light-hearted way in her videos. She reportedly began posting on TikTok to help make the process of telling others about the diagnosis easier. As she explained in an essay written for People, "Everyone was a lot more comfortable with my situation when I was laughing, and that came back around to make me feel more comfortable too."
Her content wasn't only meant for a laugh, though. Eby also made educational videos to raise awareness about her disease (much like Michiel Vandeweert did), its progression, and how everyone with it is affected in different ways. She also wanted people to know that this disease didn't discriminate by gender, age, or any other demographic, and it could affect anyone.
#brooke #videos #though
The ALS Network shared the news of Eby's death on October 1st, with a statement remembering her for the ways she built community and helped create connections through her videos and other work.
Per reporting by People, Sheri Strahl, President and CEO of ALS Network, said of Eby: "Brooke changed the way people see ALS, but she also changed the way people living with ALS find and support one another[…] Brooke changed the way people see ALS, but she also changed the way people living with ALS find and support one another."
Brooke did that by approaching ALS in a comedic and light-hearted way in her videos. She reportedly began posting on TikTok to help make the process of telling others about the diagnosis easier. As she explained in an essay written for People, "Everyone was a lot more comfortable with my situation when I was laughing, and that came back around to make me feel more comfortable too."
Her content wasn't only meant for a laugh, though. Eby also made educational videos to raise awareness about her disease (much like Michiel Vandeweert did), its progression, and how everyone with it is affected in different ways. She also wanted people to know that this disease didn't discriminate by gender, age, or any other demographic, and it could affect anyone.
#brooke #videos #though
22 days ago
Jenny Slatten's ALS battle has reached a heartbreaking new stage, with the beloved 90 Day Fiancé star now so weak that speaking has become painful—and her husband, Sumit Singh, has become her voice.
According to Page Six, the latest update came through a GoFundMe created to help cover Slatten's medical care in India, where Singh is caring for her full-time. According to Slatten's friend Penny, the 68-year-old reality star is "getting weaker by the day" while taking Edaravone and Riluzole, two medications intended to slow the progression of ALS. Penny said Slatten is also taking B12, melatonin and magnesium, but the treatments have left her drained.
"Jenny is getting weaker by the day," Penny wrote, adding that Slatten now "hardly speaks" because it hurts too much.
COMPLEX SHOP: Shop the brands you love, anytime and anywhere. Uncover what's next. Buy. Collect. Obsess.
"Sumit speaks more for her and is the main spokesperson for his wife," she continued. "Sumit is Jenny's main caregiver and doing a great job each day."
#sumit #shop
According to Page Six, the latest update came through a GoFundMe created to help cover Slatten's medical care in India, where Singh is caring for her full-time. According to Slatten's friend Penny, the 68-year-old reality star is "getting weaker by the day" while taking Edaravone and Riluzole, two medications intended to slow the progression of ALS. Penny said Slatten is also taking B12, melatonin and magnesium, but the treatments have left her drained.
"Jenny is getting weaker by the day," Penny wrote, adding that Slatten now "hardly speaks" because it hurts too much.
COMPLEX SHOP: Shop the brands you love, anytime and anywhere. Uncover what's next. Buy. Collect. Obsess.
"Sumit speaks more for her and is the main spokesperson for his wife," she continued. "Sumit is Jenny's main caregiver and doing a great job each day."
#sumit #shop
1 month ago
While an Nvidia (NASDAQ: NVDA) stock split in 2026 isn't impossible, I think it's highly unlikely. The company last completed a stock split in 2024, when its share price stood at roughly $1,200. After the 10-for-1 split, the company's stock traded at roughly $120 per share.
Currently, it's trading around $210 per share, which is likely not a high enough pure-dollar level to encourage the company to reorganize its stock structure.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
That said, I still think that Nvidia stands out as a worthwhile long-term investment.
Nvidia and other leading AI stocks have recently seen some downward valuation pressures connected to increased calls for safety guardrails and other regulations around the progression of artificial intelligence (AI) development. These technologies are evolving fast, and there are good reasons to be concerned. On the other hand, I expect that the intensifying focus on the dangers that AI poses will ultimately have a relatively small impact on Nvidia's growth trajectory.
#Stock #signal #flashing #think
Currently, it's trading around $210 per share, which is likely not a high enough pure-dollar level to encourage the company to reorganize its stock structure.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
That said, I still think that Nvidia stands out as a worthwhile long-term investment.
Nvidia and other leading AI stocks have recently seen some downward valuation pressures connected to increased calls for safety guardrails and other regulations around the progression of artificial intelligence (AI) development. These technologies are evolving fast, and there are good reasons to be concerned. On the other hand, I expect that the intensifying focus on the dangers that AI poses will ultimately have a relatively small impact on Nvidia's growth trajectory.
#Stock #signal #flashing #think
1 month ago
Galliford Try Holdings PLC (LSE:GFRD, FRA:3WC) chief financial officer Kris Hampson spoke with Proactive's Stephen Gunnion about the construction group's latest results, growing order book, margin progression and outlook for 2027, as well as its approach to acquisitions and shareholder returns.
Hampson said Galliford Try delivered a sixth consecutive year of growth across key metrics, supported by its building, infrastructure and specialist services operations. Adjusted profit before tax rose 24% on revenue growth of 3% to nearly £56 million, with adjusted divisional operating margin advancing from 3% to 3.5% and average cash up 21% to £216.2 million. "We make revenue, we turn it into profit, and we turn that profit into cash," Hampson said.
Looking ahead, he highlighted the £4.3 billion order book, up 5%, with more than 90% of current-year revenue already secured, alongside 60% for 2028. He said 91% of the order book sits within long-term frameworks and 95% is with government and regulated clients.
Hampson also discussed opportunities across water, highways, education and affordable housing, including growth tied to AMP8, newer frameworks on improved terms, and expects continued progression towards the group's 4% adjusted operating margin target for 2030.
On capital allocation, Galliford Try announced a £15 million share buyback alongside its results, following last year's £10 million buyback. Hampson also discussed the company's active M&A pipeline and its commitment to maintaining a dividend at 1.8 times cover based on adjusted EPS.
#million #profit
Hampson said Galliford Try delivered a sixth consecutive year of growth across key metrics, supported by its building, infrastructure and specialist services operations. Adjusted profit before tax rose 24% on revenue growth of 3% to nearly £56 million, with adjusted divisional operating margin advancing from 3% to 3.5% and average cash up 21% to £216.2 million. "We make revenue, we turn it into profit, and we turn that profit into cash," Hampson said.
Looking ahead, he highlighted the £4.3 billion order book, up 5%, with more than 90% of current-year revenue already secured, alongside 60% for 2028. He said 91% of the order book sits within long-term frameworks and 95% is with government and regulated clients.
Hampson also discussed opportunities across water, highways, education and affordable housing, including growth tied to AMP8, newer frameworks on improved terms, and expects continued progression towards the group's 4% adjusted operating margin target for 2030.
On capital allocation, Galliford Try announced a £15 million share buyback alongside its results, following last year's £10 million buyback. Hampson also discussed the company's active M&A pipeline and its commitment to maintaining a dividend at 1.8 times cover based on adjusted EPS.
#million #profit
1 month ago
BioNTech SE (NASDAQ:BNTX) reported that its investigational lung-cancer drug gotistobart produced a clinically meaningful overall-survival benefit in the Phase 3 PRESERVE-003 trial in patients with metastatic squamous non-small cell lung cancer whose disease had progressed after prior immunotherapy and chemotherapy. Reuters said gotistobart nearly doubled survival compared with standard-of-care chemotherapy, strengthening the case for the drug as a potential chemotherapy-free treatment in a population with significant unmet need.
The result builds on earlier Stage 1 data, where gotistobart reduced the risk of death by 54% versus docetaxel, with a hazard ratio of 0.46. Median overall survival was not yet reached for gotistobart versus 9.95 months for docetaxel, while the 12-month progression-free survival rate was 25.2% versus 0%. BioNTech is now awaiting the pivotal Stage 2 readout, making the latest result important not only for the drug's approval prospects but also for the credibility of BioNTech's broader transition from a COVID-vaccine company toward a multi-product oncology business.
The strongest bullish argument is that gotistobart now has repeated evidence of a meaningful survival advantage in a difficult-to-treat lung-cancer population. The earlier Stage 1 dataset showed 55.6% of patients alive in the gotistobart arm versus 23.8% with docetaxel, alongside a 54% reduction in the risk of death. The latest Phase 3 update reinforces that signal rather than introducing an entirely new hypothesis. If the pivotal Stage 2 data confirm the benefit, BioNTech SE (NASDAQ:BNTX) could have a differentiated therapy capable of competing on survival rather than simply response rates, potentially supporting meaningful pricing power and a commercially attractive oncology franchise.
The result also strengthens BioNTech's broader oncology strategy because gotistobart is one piece of a much larger pipeline rather than a standalone bet. BioNTech says it has 14 ongoing pivotal trials and more than 10 novel combination programs, while its lung-cancer strategy spans more than 16 ongoing clinical trials and five Phase 3 programs. Gotistobart's success therefore provides validation for the company's immuno-oncology capabilities, while other ****** ets such as pumitamig and antibody-drug conjugates advance toward additional indications. BioNTech has identified 17+ late-stage or pivotal readouts through 2030+, creating the possibility that a successful gotistobart launch becomes the first major commercial proof point in its planned transition to a multi-product oncology company.
#stage #survival
The result builds on earlier Stage 1 data, where gotistobart reduced the risk of death by 54% versus docetaxel, with a hazard ratio of 0.46. Median overall survival was not yet reached for gotistobart versus 9.95 months for docetaxel, while the 12-month progression-free survival rate was 25.2% versus 0%. BioNTech is now awaiting the pivotal Stage 2 readout, making the latest result important not only for the drug's approval prospects but also for the credibility of BioNTech's broader transition from a COVID-vaccine company toward a multi-product oncology business.
The strongest bullish argument is that gotistobart now has repeated evidence of a meaningful survival advantage in a difficult-to-treat lung-cancer population. The earlier Stage 1 dataset showed 55.6% of patients alive in the gotistobart arm versus 23.8% with docetaxel, alongside a 54% reduction in the risk of death. The latest Phase 3 update reinforces that signal rather than introducing an entirely new hypothesis. If the pivotal Stage 2 data confirm the benefit, BioNTech SE (NASDAQ:BNTX) could have a differentiated therapy capable of competing on survival rather than simply response rates, potentially supporting meaningful pricing power and a commercially attractive oncology franchise.
The result also strengthens BioNTech's broader oncology strategy because gotistobart is one piece of a much larger pipeline rather than a standalone bet. BioNTech says it has 14 ongoing pivotal trials and more than 10 novel combination programs, while its lung-cancer strategy spans more than 16 ongoing clinical trials and five Phase 3 programs. Gotistobart's success therefore provides validation for the company's immuno-oncology capabilities, while other ****** ets such as pumitamig and antibody-drug conjugates advance toward additional indications. BioNTech has identified 17+ late-stage or pivotal readouts through 2030+, creating the possibility that a successful gotistobart launch becomes the first major commercial proof point in its planned transition to a multi-product oncology company.
#stage #survival
1 month ago
BioNTech SE (NASDAQ:BNTX) reported that its investigational lung-cancer drug gotistobart produced a clinically meaningful overall-survival benefit in the Phase 3 PRESERVE-003 trial in patients with metastatic squamous non-small cell lung cancer whose disease had progressed after prior immunotherapy and chemotherapy. Reuters said gotistobart nearly doubled survival compared with standard-of-care chemotherapy, strengthening the case for the drug as a potential chemotherapy-free treatment in a population with significant unmet need.
The result builds on earlier Stage 1 data, where gotistobart reduced the risk of death by 54% versus docetaxel, with a hazard ratio of 0.46. Median overall survival was not yet reached for gotistobart versus 9.95 months for docetaxel, while the 12-month progression-free survival rate was 25.2% versus 0%. BioNTech is now awaiting the pivotal Stage 2 readout, making the latest result important not only for the drug's approval prospects but also for the credibility of BioNTech's broader transition from a COVID-vaccine company toward a multi-product oncology business.
The strongest bullish argument is that gotistobart now has repeated evidence of a meaningful survival advantage in a difficult-to-treat lung-cancer population. The earlier Stage 1 dataset showed 55.6% of patients alive in the gotistobart arm versus 23.8% with docetaxel, alongside a 54% reduction in the risk of death. The latest Phase 3 update reinforces that signal rather than introducing an entirely new hypothesis. If the pivotal Stage 2 data confirm the benefit, BioNTech SE (NASDAQ:BNTX) could have a differentiated therapy capable of competing on survival rather than simply response rates, potentially supporting meaningful pricing power and a commercially attractive oncology franchise.
The result also strengthens BioNTech's broader oncology strategy because gotistobart is one piece of a much larger pipeline rather than a standalone bet. BioNTech says it has 14 ongoing pivotal trials and more than 10 novel combination programs, while its lung-cancer strategy spans more than 16 ongoing clinical trials and five Phase 3 programs. Gotistobart's success therefore provides validation for the company's immuno-oncology capabilities, while other ***** ets such as pumitamig and antibody-drug conjugates advance toward additional indications. BioNTech has identified 17+ late-stage or pivotal readouts through 2030+, creating the possibility that a successful gotistobart launch becomes the first major commercial proof point in its planned transition to a multi-product oncology company.
#biontech #survival
The result builds on earlier Stage 1 data, where gotistobart reduced the risk of death by 54% versus docetaxel, with a hazard ratio of 0.46. Median overall survival was not yet reached for gotistobart versus 9.95 months for docetaxel, while the 12-month progression-free survival rate was 25.2% versus 0%. BioNTech is now awaiting the pivotal Stage 2 readout, making the latest result important not only for the drug's approval prospects but also for the credibility of BioNTech's broader transition from a COVID-vaccine company toward a multi-product oncology business.
The strongest bullish argument is that gotistobart now has repeated evidence of a meaningful survival advantage in a difficult-to-treat lung-cancer population. The earlier Stage 1 dataset showed 55.6% of patients alive in the gotistobart arm versus 23.8% with docetaxel, alongside a 54% reduction in the risk of death. The latest Phase 3 update reinforces that signal rather than introducing an entirely new hypothesis. If the pivotal Stage 2 data confirm the benefit, BioNTech SE (NASDAQ:BNTX) could have a differentiated therapy capable of competing on survival rather than simply response rates, potentially supporting meaningful pricing power and a commercially attractive oncology franchise.
The result also strengthens BioNTech's broader oncology strategy because gotistobart is one piece of a much larger pipeline rather than a standalone bet. BioNTech says it has 14 ongoing pivotal trials and more than 10 novel combination programs, while its lung-cancer strategy spans more than 16 ongoing clinical trials and five Phase 3 programs. Gotistobart's success therefore provides validation for the company's immuno-oncology capabilities, while other ***** ets such as pumitamig and antibody-drug conjugates advance toward additional indications. BioNTech has identified 17+ late-stage or pivotal readouts through 2030+, creating the possibility that a successful gotistobart launch becomes the first major commercial proof point in its planned transition to a multi-product oncology company.
#biontech #survival
1 month ago
The Detroit Lions will enter Week 1 with only one player carrying an injury designation for Sunday's opener against the New Orleans Saints.
Defensive back Christian Izien is questionable with a groin injury after being limited throughout the week. Everyone else listed on Detroit's final report finished Friday as a full participant and carries no game-status designation.
That includes rookie edge rusher Derrick Moore and defensive lineman Mekhi Wingo, who both progressed from limited participation Wednesday and Thursday to full participation Friday. Detroit's official final Week 1 injury report leaves Izien as the only legitimate availability question heading into the weekend.
That is a considerably cleaner injury picture than Detroit faced during much of training camp.
Moore's progression is particularly encouraging.
#injury #detroit #designation
Defensive back Christian Izien is questionable with a groin injury after being limited throughout the week. Everyone else listed on Detroit's final report finished Friday as a full participant and carries no game-status designation.
That includes rookie edge rusher Derrick Moore and defensive lineman Mekhi Wingo, who both progressed from limited participation Wednesday and Thursday to full participation Friday. Detroit's official final Week 1 injury report leaves Izien as the only legitimate availability question heading into the weekend.
That is a considerably cleaner injury picture than Detroit faced during much of training camp.
Moore's progression is particularly encouraging.
#injury #detroit #designation
1 month ago
NEW YORK — The large signage that is on the front of the world's biggest tennis stadium at the USTA Billie Jean King National Tennis Center in Flushing Meadows should tell you all you need to know about the impact of the man whose name it bears; who meant so many things to so many people during his short time on this Earth.
Arthur Ashe not only shattered barriers, he made sure that glass would never be repaired. He wanted the next generation, especially young Black Americans, to have a place in the game he loved so much.
So, when Frances Tiafoe and Ben Shelton take the court Friday night in the second US Open semifinal, it is not only a triumph for Black Americans but also for the sport of tennis.
The winner of the match will be the first Black American man to reach a US Open singles final since Ashe in 1972, and the first Black American man to reach a Grand Slam singles final since MaliVai Washington at Wimbledon in 1996.
"I think it's an exciting time," Washington said to USA TODAY Sports. "If one of them goes on to win the US Open, it will be the greatest sports story certainly of this year, and certainly of this decade. I think it shows how the growth and progression of tennis is going in the right direction. They are two great representatives of what tennis can be and what American tennis can be.
#tennis #black #open #americans
Arthur Ashe not only shattered barriers, he made sure that glass would never be repaired. He wanted the next generation, especially young Black Americans, to have a place in the game he loved so much.
So, when Frances Tiafoe and Ben Shelton take the court Friday night in the second US Open semifinal, it is not only a triumph for Black Americans but also for the sport of tennis.
The winner of the match will be the first Black American man to reach a US Open singles final since Ashe in 1972, and the first Black American man to reach a Grand Slam singles final since MaliVai Washington at Wimbledon in 1996.
"I think it's an exciting time," Washington said to USA TODAY Sports. "If one of them goes on to win the US Open, it will be the greatest sports story certainly of this year, and certainly of this decade. I think it shows how the growth and progression of tennis is going in the right direction. They are two great representatives of what tennis can be and what American tennis can be.
#tennis #black #open #americans
1 month ago
On September 3, AbbVie Inc. (NYSE:ABBV) finalized its acquisition of clinical-stage biotech Apogee Therapeutics, Inc. (NASDAQ:APGE) for $135.11 per share in cash. The $10.9 billion buyouts immediately fold Apogee's promising inflammatory and immunology (I&I) pipeline into AbbVie's commercial engine. On the exact same day, AbbVie separately reported positive Phase 3 Cervino trial results for its bispecific T-cell engager, etentamig, in relapsed/refractory multiple myeloma. Together, the dual catalysts emphasize how mega-cap pharmaceutical giants are deploying cash flow from legacy franchises to lock in next-generation immunology and oncology ***** ets.
In Q2 2026, AbbVie Inc. (NYSE:ABBV) posted $16.99 billion in net revenue, up 10.2% year over year, while adjusted diluted EPS increased 22.9% to $3.65. Growth was driven by its immunology blockbusters, Skyrizi and Rinvoq, which generated $5.505 billion and $2.525 billion in revenue, respectively, representing growth of 24.4% and 24.5%. These gains more than offset the continued decline in Humira revenue, which fell 35.9% to $756 million amid biosimilar competition. AbbVie reiterated its full-year 2026 adjusted EPS guidance of $13.87–$14.07, including a $0.14 dilutive impact from the Apogee transaction.
As a clinical-stage biotech, Apogee Therapeutics, Inc. (NASDAQ:APGE) generated no product revenue in Q2 2026, while R&D expenses reached $67.3 million and G&A expenses totaled $24.3 million, resulting in a quarterly net loss of $85.9 million. Despite the cash burn, the company maintained a strong liquidity position, with $1.3 billion in cash and marketable securities, alongside a $1.3 billion non-dilutive credit collaboration with Blackstone Life Sciences to support Phase 3 trials of its lead ***** et, zumilokibart.
Financially, AbbVie is vastly superior in immediate cash generation and profitability, whereas Apogee represented pure clinical optionality backed by robust liquidity.
For AbbVie, acquiring Apogee's optimized antibody portfolio, including zumilokibart for atopic dermatitis, strengthens its post-Humira immunology franchise. Combined with internal R&D advances such as etentamig, which achieved statistically significant overall response rate and progression-free survival results in the Phase 3 Cervino study, along with an 87.9% 12-month overall survival rate, AbbVie demonstrates potential to sustain strong organic growth.
#phase #revenue #Growth
In Q2 2026, AbbVie Inc. (NYSE:ABBV) posted $16.99 billion in net revenue, up 10.2% year over year, while adjusted diluted EPS increased 22.9% to $3.65. Growth was driven by its immunology blockbusters, Skyrizi and Rinvoq, which generated $5.505 billion and $2.525 billion in revenue, respectively, representing growth of 24.4% and 24.5%. These gains more than offset the continued decline in Humira revenue, which fell 35.9% to $756 million amid biosimilar competition. AbbVie reiterated its full-year 2026 adjusted EPS guidance of $13.87–$14.07, including a $0.14 dilutive impact from the Apogee transaction.
As a clinical-stage biotech, Apogee Therapeutics, Inc. (NASDAQ:APGE) generated no product revenue in Q2 2026, while R&D expenses reached $67.3 million and G&A expenses totaled $24.3 million, resulting in a quarterly net loss of $85.9 million. Despite the cash burn, the company maintained a strong liquidity position, with $1.3 billion in cash and marketable securities, alongside a $1.3 billion non-dilutive credit collaboration with Blackstone Life Sciences to support Phase 3 trials of its lead ***** et, zumilokibart.
Financially, AbbVie is vastly superior in immediate cash generation and profitability, whereas Apogee represented pure clinical optionality backed by robust liquidity.
For AbbVie, acquiring Apogee's optimized antibody portfolio, including zumilokibart for atopic dermatitis, strengthens its post-Humira immunology franchise. Combined with internal R&D advances such as etentamig, which achieved statistically significant overall response rate and progression-free survival results in the Phase 3 Cervino study, along with an 87.9% 12-month overall survival rate, AbbVie demonstrates potential to sustain strong organic growth.
#phase #revenue #Growth
1 month ago
Michigan news: Brian Kelly urges offensive change to fit Bryce Underwood appeared first on ClutchPoints. Add ClutchPoints as a Preferred Source by clicking here.
Brian Kelly knows Bryce Underwood's skill set better than most, and the former LSU coach thinks Michigan needs to make some changes.
Kelly recruited Underwood for two years and initially landed his commitment at LSU before the five-star quarterback ultimately flipped to Michigan. After watching Underwood struggle in Michigan's 13-12 Week 1 escape against Western Michigan, Kelly believes the Wolverines need to better utilize their quarterback's athleticism.
"He committed to me at LSU. I recruited him for two years, so I know him very well. He is an elite athlete," Kelly said on The Early Read with Danny Kanell and Roy Philpott on Sirius XM. "I mean, athletically off the charts… He's not a drop-back quarterback that's gonna sit there and read through progressions. He's a half-line guy. You need to keep him on the move. You need to run him. You gotta run this kid. He is big, physical, strong, and fast, and he's tough."
Watch sports LIVE with fuboTV (free trial)
#michigan #underwood #clutchpoints #recruited
Brian Kelly knows Bryce Underwood's skill set better than most, and the former LSU coach thinks Michigan needs to make some changes.
Kelly recruited Underwood for two years and initially landed his commitment at LSU before the five-star quarterback ultimately flipped to Michigan. After watching Underwood struggle in Michigan's 13-12 Week 1 escape against Western Michigan, Kelly believes the Wolverines need to better utilize their quarterback's athleticism.
"He committed to me at LSU. I recruited him for two years, so I know him very well. He is an elite athlete," Kelly said on The Early Read with Danny Kanell and Roy Philpott on Sirius XM. "I mean, athletically off the charts… He's not a drop-back quarterback that's gonna sit there and read through progressions. He's a half-line guy. You need to keep him on the move. You need to run him. You gotta run this kid. He is big, physical, strong, and fast, and he's tough."
Watch sports LIVE with fuboTV (free trial)
#michigan #underwood #clutchpoints #recruited
0.00$ raised of 0.00$ goal
0 donations
0.00$
to go
1 month ago
Let's just get this out of the way: Mark Wahlberg is as A-list as it gets. He broke out in 1997's "Boogie Nights," and in the nearly three decades since, he's built one of the highest-wattage careers in Hollywood: two Academy Award nominations, a Golden Globe nod for "The Fighter," multiple Emmy nominations as a producer (HBO's "Entourage" among them), and a filmography that spans crime dramas, comedies, and action blockbusters. Right now, he's back on screen in "By Any Means," a manhunt thriller set during the 1966 Mississippi civil rights killings.
He's also signaling where he's increasingly turning his attention. Wahlberg will sit down with Bruce K. Lee, Founder and CEO of Keebeck Wealth Management, on the main stage at TechCrunch Disrupt 2026 to talk about his own progression. Grab your ticket here so you don't miss a moment of this session and Disrupt 2026. Ticket prices increase on September 25.
Image Credits:TechCrunch
His acting career is really just part of the picture. Over the past two decades, Wahlberg has built a production company, a restaurant chain, apparel and fitness ventures, a slate of angel investments, and the now 25-year-old Mark Wahlberg Youth Foundation, which supports inner-city kids and teens. He's used his Hollywood success to launch big projects well outside the movie business — and in a fireside chat at this year's Disrupt, he's going to give us a peek into how.
Wahlberg, who's leaned almost entirely on entrepreneurial instinct about people, culture, products, and markets, is now someone who's been building institutional-level investing discipline, with Lee as his guide, and with a growing focus on healthcare and wellness startups. It's a rare, unvarnished look at how someone with Wahlberg's cultural intelligence has worked his way into some of the most sophisticated rooms in business and finance.
#techcrunch #ticket #decades #nominations
He's also signaling where he's increasingly turning his attention. Wahlberg will sit down with Bruce K. Lee, Founder and CEO of Keebeck Wealth Management, on the main stage at TechCrunch Disrupt 2026 to talk about his own progression. Grab your ticket here so you don't miss a moment of this session and Disrupt 2026. Ticket prices increase on September 25.
Image Credits:TechCrunch
His acting career is really just part of the picture. Over the past two decades, Wahlberg has built a production company, a restaurant chain, apparel and fitness ventures, a slate of angel investments, and the now 25-year-old Mark Wahlberg Youth Foundation, which supports inner-city kids and teens. He's used his Hollywood success to launch big projects well outside the movie business — and in a fireside chat at this year's Disrupt, he's going to give us a peek into how.
Wahlberg, who's leaned almost entirely on entrepreneurial instinct about people, culture, products, and markets, is now someone who's been building institutional-level investing discipline, with Lee as his guide, and with a growing focus on healthcare and wellness startups. It's a rare, unvarnished look at how someone with Wahlberg's cultural intelligence has worked his way into some of the most sophisticated rooms in business and finance.
#techcrunch #ticket #decades #nominations
0.00$ raised of 0.00$ goal
0 donations
0.00$
to go
1 month ago
In one of the first deviations from John Harbaugh's usual approach, the Baltimore Ravens did not hold a full practice Thursday, but their estimated injury report included an encouraging development ahead of Sunday's season opener against the Indianapolis Colts.
Wide receiver Zay Flowers was listed as a full participant after being listed as a limited participant Wednesday because of a hamstring injury. The upgrade places him on track to play barring a setback during the remainder of the week.
Because Baltimore held a walkthrough, Thursday's participation levels projected how much work each player would handle during a traditional practice. Linebacker Teddye Buchanan was listed as a limited participant for the second consecutive day because of a knee injury. Defensive tackle Nnamdi Madubuike was also listed as a limited participant again with a neck injury.
We held a walkthrough on Thursday; our report is a practice estimation. pic.twitter.com/ZUyydo6ZlW
Madubuike's availability will be particularly important against Jonathan Taylor and the Colts' powerful rushing attack. The defensive tackle missed the final 15 games of the 2025 season, making his progression one of Baltimore's most significant Week 1 storylines. Wide receiver Devontez Walker was listed as a limited participant for the second consecutive day with a groin injury. His status could affect Baltimore's receiving rotation and special teams plans.
#participant #limited #wide
Wide receiver Zay Flowers was listed as a full participant after being listed as a limited participant Wednesday because of a hamstring injury. The upgrade places him on track to play barring a setback during the remainder of the week.
Because Baltimore held a walkthrough, Thursday's participation levels projected how much work each player would handle during a traditional practice. Linebacker Teddye Buchanan was listed as a limited participant for the second consecutive day because of a knee injury. Defensive tackle Nnamdi Madubuike was also listed as a limited participant again with a neck injury.
We held a walkthrough on Thursday; our report is a practice estimation. pic.twitter.com/ZUyydo6ZlW
Madubuike's availability will be particularly important against Jonathan Taylor and the Colts' powerful rushing attack. The defensive tackle missed the final 15 games of the 2025 season, making his progression one of Baltimore's most significant Week 1 storylines. Wide receiver Devontez Walker was listed as a limited participant for the second consecutive day with a groin injury. His status could affect Baltimore's receiving rotation and special teams plans.
#participant #limited #wide
0.00$ raised of 0.00$ goal
0 donations
0.00$
to go
2 months ago
Shohei Ohtani is dealing with some injuries that have kept him off the mound for the Los Angeles Dodgers, but lately, his hitting has not been great.
With Ohtani reporting some discomfort in his right biceps and neck after a four-strikeout game on Wednesday, the Dodgers gave him four days off. In that time, the team has reportedly decided that it's unlikely he will pitch again this season.
"I'm going to be focusing on hitting moving forward," Ohtani said through interpreter Will Ireton on Monday, per The Athletic's Fabian Ardaya.
Ohtani has a 1.79 ERA through 14 starts this year, so the Dodgers are actually losing a very valuable arm. He has gone at least six innings in 13 of his starts, but at this point, his offense is more valuable to the team. The injuries that had kept him off the mound were starting to impact his swing, and a throwing progression was clearly not helping that.
Looking for the perfect gift for a baseball player in your life? Check out our brand-new baseball lifestyle brand!
#Dodgers #team #valuable
With Ohtani reporting some discomfort in his right biceps and neck after a four-strikeout game on Wednesday, the Dodgers gave him four days off. In that time, the team has reportedly decided that it's unlikely he will pitch again this season.
"I'm going to be focusing on hitting moving forward," Ohtani said through interpreter Will Ireton on Monday, per The Athletic's Fabian Ardaya.
Ohtani has a 1.79 ERA through 14 starts this year, so the Dodgers are actually losing a very valuable arm. He has gone at least six innings in 13 of his starts, but at this point, his offense is more valuable to the team. The injuries that had kept him off the mound were starting to impact his swing, and a throwing progression was clearly not helping that.
Looking for the perfect gift for a baseball player in your life? Check out our brand-new baseball lifestyle brand!
#Dodgers #team #valuable
2 months ago
There is something extra fun about watching a basketball season develop in real time. That's especially true with the New York Knicks. Before the standings settle in and the familiar stars dominate every conversation, younger players are waiting for their chance to change how they're viewed.
That process can be one of the best parts of following the NBA. A player can begin the year as someone most people barely mention and finish it as someone fans are suddenly wondering how they ever overlooked. Those are the kinds of players who can eventually become the Jalen Brunsons of the league, growing from developing pieces into major contributors against the Knicks' competition.
The Knicks have two players who could be worth following closely for that reason: Tyler Kolek and Mohamed Diawara.
Kolek is heading into Year 2 at point guard, and there are already signs that the Knicks see something worth developing. One detail from the offseason stands out. Kolek didn't participate in Summer League, which has been viewed as an indication that the organization has greater confidence in his development. Instead of needing another extended audition, he appears to be moving toward the next stage of his progression.
That doesn't necessarily mean he'll suddenly become one of New York's most important players when the games start. There are veteran ball-handlers in front of him, and earning regular playing time in an NBA rotation is never quite as simple as it looks from the outside.
#knicks
That process can be one of the best parts of following the NBA. A player can begin the year as someone most people barely mention and finish it as someone fans are suddenly wondering how they ever overlooked. Those are the kinds of players who can eventually become the Jalen Brunsons of the league, growing from developing pieces into major contributors against the Knicks' competition.
The Knicks have two players who could be worth following closely for that reason: Tyler Kolek and Mohamed Diawara.
Kolek is heading into Year 2 at point guard, and there are already signs that the Knicks see something worth developing. One detail from the offseason stands out. Kolek didn't participate in Summer League, which has been viewed as an indication that the organization has greater confidence in his development. Instead of needing another extended audition, he appears to be moving toward the next stage of his progression.
That doesn't necessarily mean he'll suddenly become one of New York's most important players when the games start. There are veteran ball-handlers in front of him, and earning regular playing time in an NBA rotation is never quite as simple as it looks from the outside.
#knicks
2 months ago
Borussia Dortmund did it the hard way today in only their second match of the season. Away to Hoffenheim, the Black and Yellows went two goals behind, leaving it all to do with thirty minutes to play. Waldemar Anton took charge, sporting the captain's armband, blasting through the Hoffenheim defense at a lax moment to nick a loose ball and square it for Serhou Guirassy, who got the comeback started. BVB would find two further goals from Fabio Silva, and an own goal created by some intelligent interplay between Silva and Nwaneri.
The defense today was… not exactly sterling. The injury to Mane unsettled the back line, and despite some bright spots specifically from Gadou in progression, there were also some calamitous errors that gave Hoffenheim control of the momentum. Anton has been given the tricky task of leading a young, inexperienced back line. Gadou and Mane are talented, but they are both really in their first seasons of top flight football. Anton needs to keep them in check and handle his defensive duties as well. It's a lot of responsibity for BVB's stand-in captain. Anton's tenacity to win the ball high up the pitch got his team back into the game, and he deserves credit for his efforts across the pitch.
An additional note on Mane. I'm worried about this kid. Two hamstring injuries in only a few professional matches point to either a more serious issue, or insufficient preparation from the physio team. Mane has looked promising in the lead up to the season, but these injuries threaten to derail his career. BVB need to get their well-paid medical staff to figure out what's going on here.
Anyone seen the midfield? I can't seem to find it.
I'm not sure if we blame Kovac here, blame the players, blame the system, but my goodness where is our central spine? Hoffenheim ran down the throat of the BVB defense for the entire first half because there seemed to be no cover in front of it. Maybe we will see more of Veerman in the weeks to come, but it's not like the dutchman is some deep-lying enforcer—he is a creator. If BVB are going to be fielding a juvenile back line for the next few weeks (they are), the midfield needs to provide some better cover.
#line #silva #gadou #today
The defense today was… not exactly sterling. The injury to Mane unsettled the back line, and despite some bright spots specifically from Gadou in progression, there were also some calamitous errors that gave Hoffenheim control of the momentum. Anton has been given the tricky task of leading a young, inexperienced back line. Gadou and Mane are talented, but they are both really in their first seasons of top flight football. Anton needs to keep them in check and handle his defensive duties as well. It's a lot of responsibity for BVB's stand-in captain. Anton's tenacity to win the ball high up the pitch got his team back into the game, and he deserves credit for his efforts across the pitch.
An additional note on Mane. I'm worried about this kid. Two hamstring injuries in only a few professional matches point to either a more serious issue, or insufficient preparation from the physio team. Mane has looked promising in the lead up to the season, but these injuries threaten to derail his career. BVB need to get their well-paid medical staff to figure out what's going on here.
Anyone seen the midfield? I can't seem to find it.
I'm not sure if we blame Kovac here, blame the players, blame the system, but my goodness where is our central spine? Hoffenheim ran down the throat of the BVB defense for the entire first half because there seemed to be no cover in front of it. Maybe we will see more of Veerman in the weeks to come, but it's not like the dutchman is some deep-lying enforcer—he is a creator. If BVB are going to be fielding a juvenile back line for the next few weeks (they are), the midfield needs to provide some better cover.
#line #silva #gadou #today
2 months ago
Revolution Medicines, Inc. (NASDAQ:RVMD) received FDA approval for Rasonque, or daraxonrasib, following an expedited review. The once-daily oral RAS inhibitor is approved for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
Revolution Medicines, Inc. (NASDAQ:RVMD) set a wholesale acquisition cost (WAC) of $39,800 for a 30-day supply. Twelve 30-day supplies would total $477,600 at WAC before discounts, rebates, or ******* istance. Rasonque is available in the United States, with (ON)Path offering insurance navigation and financial-assistance resources, including copay support for eligible commercially insured patients.
The approval was based on RASolute 302, a randomized Phase 3 trial involving 500 patients with previously treated metastatic pancreatic adenocarcinoma. In the overall population, median overall survival reached 13.2 months with Rasonque versus 6.7 months with chemotherapy. The hazard ratio of 0.40 represented a 60% lower hazard of death during trial follow-up. Median progression-free survival was 7.2 months versus 3.6 months, while objective response rates were 30% and 11%, respectively.
The survival benefit gives Rasonque a strong clinical argument for reimbursement. Pancreatic cancer is aggressive, treatment options after progression are limited, and Rasonque improved overall survival, progression-free survival, and response rates in a randomized comparison. Oral dosing may also reduce the burden of intravenous chemotherapy.
The approved population is broader than a single mutation-defined subgroup. Rasonque can be prescribed with or without an identified RAS tumor mutation and does not require a companion diagnostic. That reduces testing friction within the approved treatment setting.
#months #pancreatic #progression #medicines
Revolution Medicines, Inc. (NASDAQ:RVMD) set a wholesale acquisition cost (WAC) of $39,800 for a 30-day supply. Twelve 30-day supplies would total $477,600 at WAC before discounts, rebates, or ******* istance. Rasonque is available in the United States, with (ON)Path offering insurance navigation and financial-assistance resources, including copay support for eligible commercially insured patients.
The approval was based on RASolute 302, a randomized Phase 3 trial involving 500 patients with previously treated metastatic pancreatic adenocarcinoma. In the overall population, median overall survival reached 13.2 months with Rasonque versus 6.7 months with chemotherapy. The hazard ratio of 0.40 represented a 60% lower hazard of death during trial follow-up. Median progression-free survival was 7.2 months versus 3.6 months, while objective response rates were 30% and 11%, respectively.
The survival benefit gives Rasonque a strong clinical argument for reimbursement. Pancreatic cancer is aggressive, treatment options after progression are limited, and Rasonque improved overall survival, progression-free survival, and response rates in a randomized comparison. Oral dosing may also reduce the burden of intravenous chemotherapy.
The approved population is broader than a single mutation-defined subgroup. Rasonque can be prescribed with or without an identified RAS tumor mutation and does not require a companion diagnostic. That reduces testing friction within the approved treatment setting.
#months #pancreatic #progression #medicines
2 months ago
Sergio Martinez could make one of the most unexpected Real Madrid debuts in recent years when Jose Mourinho's side face Inter Milan in their Champions League opener on Tuesday.
The midfielder only joined Madrid from Racing Santander days ago, but his rise has already taken him from the reserve setup to the senior squad.
According to MARCA, Martinez has trained with Mourinho's first-team group and is now in contention for the European fixture at the Santiago Bernabeu.
Notably, his inclusion on Madrid's Champions League A-list has accelerated that progression even further.
Martinez's rise has been driven partly by circumstances within Mourinho's squad.
#martinez #squad
The midfielder only joined Madrid from Racing Santander days ago, but his rise has already taken him from the reserve setup to the senior squad.
According to MARCA, Martinez has trained with Mourinho's first-team group and is now in contention for the European fixture at the Santiago Bernabeu.
Notably, his inclusion on Madrid's Champions League A-list has accelerated that progression even further.
Martinez's rise has been driven partly by circumstances within Mourinho's squad.
#martinez #squad
2 months ago
LOS ANGELES (AP) — The Los Angeles Dodgers remain uncertain whether designated hitter Shohei Ohtani will pitch again this season.
The two-way superstar hasn't pitched in a game since July 3 because of lingering pain in his left knee and right biceps. Ohtani threw a 20-pitch bullpen session last Friday but was scratched from a potential start at Detroit two days later.
"I think physically he's in a good spot," manager Dave Roberts said Wednesday. "I haven't heard otherwise as far as him ailing, whether it's the arm, the knee. Everything that he's told me and the training staff, he feels good."
Roberts said that until he sees Ohtani throw another bullpen he won't know the next step in his pitching progression.
Asked if it's possible Ohtani won't pitch again this season, Roberts said, "It's an option."
#whether #season
The two-way superstar hasn't pitched in a game since July 3 because of lingering pain in his left knee and right biceps. Ohtani threw a 20-pitch bullpen session last Friday but was scratched from a potential start at Detroit two days later.
"I think physically he's in a good spot," manager Dave Roberts said Wednesday. "I haven't heard otherwise as far as him ailing, whether it's the arm, the knee. Everything that he's told me and the training staff, he feels good."
Roberts said that until he sees Ohtani throw another bullpen he won't know the next step in his pitching progression.
Asked if it's possible Ohtani won't pitch again this season, Roberts said, "It's an option."
#whether #season
2 months ago
Shohei Ohtani is expected to have an impact on the postseason as the Los Angeles Dodgers continue their quest for a World Series three-peat.
What opportunities Ohtani might have to make an impact remain uncertain.
Ohtani appeared to be trending in the right direction with his pitching progression, but that was put to a halt on Aug. 29. Dodgers manager Dave Roberts announced that the team's two-way star would not be making a return as it was anticipated. The pitcher had thrown a 20-pitch bullpen just the day before.
In a Sept. 2 conversation with reporters, Roberts said the team is still considering shutting down Ohtani, but the Dodgers aren't ready to make that decision.
"I know he is in lockstep with (Mark Prior), the pitching guys, the training staff, but I think for me he has to throw a bullpen, then we will see the next progression," Roberts said.
#ohtani #progression #shohei
What opportunities Ohtani might have to make an impact remain uncertain.
Ohtani appeared to be trending in the right direction with his pitching progression, but that was put to a halt on Aug. 29. Dodgers manager Dave Roberts announced that the team's two-way star would not be making a return as it was anticipated. The pitcher had thrown a 20-pitch bullpen just the day before.
In a Sept. 2 conversation with reporters, Roberts said the team is still considering shutting down Ohtani, but the Dodgers aren't ready to make that decision.
"I know he is in lockstep with (Mark Prior), the pitching guys, the training staff, but I think for me he has to throw a bullpen, then we will see the next progression," Roberts said.
#ohtani #progression #shohei
2 months ago
Week 1 of the NFL season is on the horizon and we're about to enter the REAL start of the college football season this weekend. But it's not too early to peek at the talent expected to hear their names called in the 2027 NFL Draft.
Here is my first big board, ranking players Nos. 1-31 and a list of 10 to watch who could break into the mix later this season. Why 31 instead of 30? You'll see why I gave both of those ranked players, each quarterbacks, some shine.
Manning is an excellent athlete with size. He plays with a proper timing on plays when working from the pocket, but he can also throw consistently on the move and has the toughness and core strength to get any throw off no matter his platform or how muddy the pocket is or how he is getting hit. He has a good arm that he unlocks because of his creativity, ability to anticipate and willingness to push the football down the field. Manning's quick throwing motion unlocks underneath throws and he already has advanced feel in the pocket. He constantly keeps his eyes downfield, which allows him to get the ball off and avoid sacks, turning negative plays to positive, or even explosive ones.
His progression as a player was overlooked last year after an early-season loss to Ohio State and Texas having to gut out several wins, but his play, along with his tools, indicated a future No. 1 draft pick despite what looked like lackluster performances. There's a lot of hype, but he looks like he's worth it.
A force of nature at receiver, Smith has been a standout player and absurdly productive at every level of his career. He is strong, explosive, and has an excellent build that allows him to bounce off tackles and constantly eat up yards after the catch. His power as a player makes him dangerous on in-breakers that allow him to build up speed and get downhill in a hurry, and his speed and burst out of breaks make him dangerous. Even without pristine route refinement, Smith is still dominant. It's hard to compare any athlete to Julio Jones, and welp, here we are with Smith. At worst you're looking at a Josh Gordon-like player.
#player #like
Here is my first big board, ranking players Nos. 1-31 and a list of 10 to watch who could break into the mix later this season. Why 31 instead of 30? You'll see why I gave both of those ranked players, each quarterbacks, some shine.
Manning is an excellent athlete with size. He plays with a proper timing on plays when working from the pocket, but he can also throw consistently on the move and has the toughness and core strength to get any throw off no matter his platform or how muddy the pocket is or how he is getting hit. He has a good arm that he unlocks because of his creativity, ability to anticipate and willingness to push the football down the field. Manning's quick throwing motion unlocks underneath throws and he already has advanced feel in the pocket. He constantly keeps his eyes downfield, which allows him to get the ball off and avoid sacks, turning negative plays to positive, or even explosive ones.
His progression as a player was overlooked last year after an early-season loss to Ohio State and Texas having to gut out several wins, but his play, along with his tools, indicated a future No. 1 draft pick despite what looked like lackluster performances. There's a lot of hype, but he looks like he's worth it.
A force of nature at receiver, Smith has been a standout player and absurdly productive at every level of his career. He is strong, explosive, and has an excellent build that allows him to bounce off tackles and constantly eat up yards after the catch. His power as a player makes him dangerous on in-breakers that allow him to build up speed and get downhill in a hurry, and his speed and burst out of breaks make him dangerous. Even without pristine route refinement, Smith is still dominant. It's hard to compare any athlete to Julio Jones, and welp, here we are with Smith. At worst you're looking at a Josh Gordon-like player.
#player #like
2 months ago
Newcastle United have signed forward Matias Fernandez-Pardo from Lille for an initial £51.4m.
Fernandez-Pardo flew into Tyneside on Monday night to have a medical and sign a long-term contract.
The 21-year-old said he was "very proud to be at such a big club" following talks with head coach Matthias Jaissle.
"He really showed how much he wanted me to be here," the Belgium international said.
"In terms of my own career progression, it made complete sense to come so I didn't hesitate at all.
#jaissle
Fernandez-Pardo flew into Tyneside on Monday night to have a medical and sign a long-term contract.
The 21-year-old said he was "very proud to be at such a big club" following talks with head coach Matthias Jaissle.
"He really showed how much he wanted me to be here," the Belgium international said.
"In terms of my own career progression, it made complete sense to come so I didn't hesitate at all.
#jaissle
2 months ago
When the Arizona Cardinals announced their 53-man roster on Sunday, Aug. 30, it laid bare the cracks in this team's foundation. At multiple key spots, the Cardinals are short on both impact starters and reliable depth pieces.
That much, though, was already known. What's new is the 34 players whom the Cardinals cut, along with two minor trades and four injury designations. Each move played a part in carving the group of 53 players that will face the Los Angeles Chargers in Week 1 on Sept. 13 — although waiver claims could tweak the picture this week.
For now, here are five key takeaways from the roster release.
The biggest news of the day came when the Cardinals placed veteran running back James Conner on injured reserve, ruling him out of the first four games. That much, though, has little to do with Jeremiyah Love. Conner didn't participate in 11-on-11 drills for all of camp, and hadn't practiced at all over the past week. His progression has simply taken longer than expected.
The notable part, for Love, is that the Cardinals opted to keep just three running backs in Conner's absence, as they traded away Corey Kiner and released Evan Hull.
#though
That much, though, was already known. What's new is the 34 players whom the Cardinals cut, along with two minor trades and four injury designations. Each move played a part in carving the group of 53 players that will face the Los Angeles Chargers in Week 1 on Sept. 13 — although waiver claims could tweak the picture this week.
For now, here are five key takeaways from the roster release.
The biggest news of the day came when the Cardinals placed veteran running back James Conner on injured reserve, ruling him out of the first four games. That much, though, has little to do with Jeremiyah Love. Conner didn't participate in 11-on-11 drills for all of camp, and hadn't practiced at all over the past week. His progression has simply taken longer than expected.
The notable part, for Love, is that the Cardinals opted to keep just three running backs in Conner's absence, as they traded away Corey Kiner and released Evan Hull.
#though
2 months ago
Well, this is something to wake up to. According to The Athletic's David Ornstein, overnight Tottenham Hotspur and Everton reached an agreement to essentially swap attackers — bringing Ilman Ndiaye to Spurs, with Richarlison returning to Everton heading the other direction. This is NOT a true swap deal; these will be treated as separate transfers.
In yesterday's post-match press conference, Spurs head coach Roberto De Zerbi essentially told us that Richarlison asked to leave Spurs for a new challenge. I just didn't realize it would all go down so quickly. According to Paul Joyce of The Times, Ndiaye will cost Spurs about £60m, with Richarlison heading the other direction for a fee of £35m, making the outlay a lot lower than most transfers that Spurs have brought in this summer.
Ndiaye, 26, is a French fooballer who has declared for and plays international football for Senegal. He's been used primarily on the left wing for Everton, but can also play centrally or on the right. He's NOT a striker but could be implemented as a #10 if needed. Ndiaye likes to be on the ball and frequently prefers to take on and dribble past his defenders, which frequently turns into touches in the penalty area and shots. He likes to cut inside from the flank and is also comfortable receiving the ball deeper as a ball progression outlet. His acquisition means that Spurs will essentially only have three first team strikers on the books — Omar Marmoush, Dominic Solanke, and Dane Scarlett — but Ndiaye will fortify Spurs' attacking midfield options. His preferred position at Everton will put him in competition with Mathys Tel and Savinho, but his positional flexibility means he could be an ***** et elsewhere as well. He's also a willing presser and capable of putting in defensive work to make tackles. Despite maybe hinting otherwise yesterday, I'm kind of a fan of this deal.
As for Richarlison… well, I'm sad. He's probably my favorite Spurs player (non-Sonny edition) of this era. He's a vibes guy who always seemed to lift the mood, and it's clear he loved Spurs. But it's just as clear that he's not happy here anymore, and as his career starts to wind down a return to the club that lifted him to stardom feels like the closing of the circle. Everton fans love him as much as we do, and I can't begrudge them, or him, this move. It feels like the right choice.
What do you think of this deal? Can Spurs get it across the line before the window closes on September 2?
#everton #ndiaye
In yesterday's post-match press conference, Spurs head coach Roberto De Zerbi essentially told us that Richarlison asked to leave Spurs for a new challenge. I just didn't realize it would all go down so quickly. According to Paul Joyce of The Times, Ndiaye will cost Spurs about £60m, with Richarlison heading the other direction for a fee of £35m, making the outlay a lot lower than most transfers that Spurs have brought in this summer.
Ndiaye, 26, is a French fooballer who has declared for and plays international football for Senegal. He's been used primarily on the left wing for Everton, but can also play centrally or on the right. He's NOT a striker but could be implemented as a #10 if needed. Ndiaye likes to be on the ball and frequently prefers to take on and dribble past his defenders, which frequently turns into touches in the penalty area and shots. He likes to cut inside from the flank and is also comfortable receiving the ball deeper as a ball progression outlet. His acquisition means that Spurs will essentially only have three first team strikers on the books — Omar Marmoush, Dominic Solanke, and Dane Scarlett — but Ndiaye will fortify Spurs' attacking midfield options. His preferred position at Everton will put him in competition with Mathys Tel and Savinho, but his positional flexibility means he could be an ***** et elsewhere as well. He's also a willing presser and capable of putting in defensive work to make tackles. Despite maybe hinting otherwise yesterday, I'm kind of a fan of this deal.
As for Richarlison… well, I'm sad. He's probably my favorite Spurs player (non-Sonny edition) of this era. He's a vibes guy who always seemed to lift the mood, and it's clear he loved Spurs. But it's just as clear that he's not happy here anymore, and as his career starts to wind down a return to the club that lifted him to stardom feels like the closing of the circle. Everton fans love him as much as we do, and I can't begrudge them, or him, this move. It feels like the right choice.
What do you think of this deal? Can Spurs get it across the line before the window closes on September 2?
#everton #ndiaye
2 months ago
On August 13, Celcuity (NASDAQ:CELC) walked investors through a quarter unlike any in the company's history. The clinical-stage biotech is no longer just clinical: its breast cancer drug Revtopik won FDA approval on July 14, and the call was built around how the company plans to turn that approval into an actual business. The tone was confident, but the numbers underneath told a more complicated story about what launching a first drug really costs.
The regulatory news alone stood out. The FDA approved Revtopik on July 14 for patients with HR positive, HER2-negative advanced breast cancer without a PIK3CA mutation who had progressed on prior endocrine therapy. Less than three weeks later, the National Comprehensive Cancer Network recommended both the Revtopik triplet and doublet as preferred Category 1 options for second-line treatment, a fast endorsement suggesting oncologists see real value here.
That value shows up in the data. In the PIK3CA mutant cohort of the VIKTORIA-1 trial, the gedatolisib triplet produced a median progression-free survival of 11.1 months versus 5.6 months for alpelisib plus fulvestrant, cutting the risk of progression or death in half. Just 5.2% of triplet patients and 3.8% of doublet patients stopped treatment due to side effects, compared to 19% on alpelisib. CEO Sullivan said that 4% to 5% range "best represents what we expect to see in a real world setting," a detail that matters because patients who stay on a drug longer generate more revenue over time.
Celcuity is not stopping at second-line treatment either. The VIKTORIA-2 trial has been expanded to test gedatolisib in treatment-naive, endocrine-sensitive patients, a group that makes up roughly two-thirds of newly diagnosed advanced breast cancer cases each year. That bet is backed by earlier Phase 1b data showing a median progression-free survival of 48.6 months, nearly double the roughly 25 months typical of current standard of care. Commercially, the company says its 80-person oncology sales team, averaging 24 years of experience, is fully built, backed by $754 million in cash management expects to last into 2029.
Turning that approval into revenue has been expensive. Net loss widened to $78.9 million, or $1.44 per share, for the quarter, compared to a loss of $45.3 million a year earlier. Selling, general, and administrative expenses jumped $27.4 million to $35 million, driven mostly by hiring the commercial team needed to support the launch. Celcuity has not shipped a single vial yet, with shipments not expected to begin until late in the third quarter of 2026.
#cancer #months #quarter
The regulatory news alone stood out. The FDA approved Revtopik on July 14 for patients with HR positive, HER2-negative advanced breast cancer without a PIK3CA mutation who had progressed on prior endocrine therapy. Less than three weeks later, the National Comprehensive Cancer Network recommended both the Revtopik triplet and doublet as preferred Category 1 options for second-line treatment, a fast endorsement suggesting oncologists see real value here.
That value shows up in the data. In the PIK3CA mutant cohort of the VIKTORIA-1 trial, the gedatolisib triplet produced a median progression-free survival of 11.1 months versus 5.6 months for alpelisib plus fulvestrant, cutting the risk of progression or death in half. Just 5.2% of triplet patients and 3.8% of doublet patients stopped treatment due to side effects, compared to 19% on alpelisib. CEO Sullivan said that 4% to 5% range "best represents what we expect to see in a real world setting," a detail that matters because patients who stay on a drug longer generate more revenue over time.
Celcuity is not stopping at second-line treatment either. The VIKTORIA-2 trial has been expanded to test gedatolisib in treatment-naive, endocrine-sensitive patients, a group that makes up roughly two-thirds of newly diagnosed advanced breast cancer cases each year. That bet is backed by earlier Phase 1b data showing a median progression-free survival of 48.6 months, nearly double the roughly 25 months typical of current standard of care. Commercially, the company says its 80-person oncology sales team, averaging 24 years of experience, is fully built, backed by $754 million in cash management expects to last into 2029.
Turning that approval into revenue has been expensive. Net loss widened to $78.9 million, or $1.44 per share, for the quarter, compared to a loss of $45.3 million a year earlier. Selling, general, and administrative expenses jumped $27.4 million to $35 million, driven mostly by hiring the commercial team needed to support the launch. Celcuity has not shipped a single vial yet, with shipments not expected to begin until late in the third quarter of 2026.
#cancer #months #quarter
2 months ago
The Scottish Premiership returns for 10 clubs this weekend after only two sides played last time out.
Five clubs were given more time to prepare for European play-off fixtures and, while Hearts succeeded in their task of progression, Rangers, Hibernian and Motherwell all missed out on the Conference League.
Celtic crumbled in the second leg of their Champions League play-off against LASK, although they have the compensation of still being in Europe in the Europa League.
Those midweek results beg questions before Saturday and Sunday's games.
Celtic face Benfica & Hearts meet Trabzonspor
#play #scottish
Five clubs were given more time to prepare for European play-off fixtures and, while Hearts succeeded in their task of progression, Rangers, Hibernian and Motherwell all missed out on the Conference League.
Celtic crumbled in the second leg of their Champions League play-off against LASK, although they have the compensation of still being in Europe in the Europa League.
Those midweek results beg questions before Saturday and Sunday's games.
Celtic face Benfica & Hearts meet Trabzonspor
#play #scottish
2 months ago
On August 13, Capricor Therapeutics (NASDAQ:CAPR) held its second-quarter earnings call, just over two weeks after an FDA advisory committee voted 3 to 9 against the company's bid to treat cardiomyopathy in ****** nne muscular dystrophy patients on July 29. That rejection forced a strategic pivot. Management now plans to amend its Biologics License Application to pursue a narrower upper limb skeletal muscle indication, the same measure that carried the HOPE-3 trial's primary endpoint. The shift extends the regulatory timeline, but it also puts the spotlight back on the data that held up best.
Deramiocel's case still rests on real numbers. The HOPE-3 primary endpoint showed a statistically significant slowing of upper limb disease progression, with a 4.5% mean difference favoring the drug and a p-value of 0.029. During a separate advisory committee discussion, feedback on upper limb function was described as directionally supportive of that evidence. The cardiomyopathy subgroup's ejection fraction data held too, showing a 2.8 percentage point treatment difference at a p-value of 0.02, unchanged from the original ****** ysis.
Safety data spans more than 1,300 intravenous infusions across over 200 patients in three clinical trials, with more than 80 patients enrolled in open-label extension studies, some receiving infusions for over five years. The full HOPE-3 data set was published in The Lancet in July following independent peer review. The FDA has indicated it will review the coming BLA amendment and extend the PDUFA date accordingly, and Capricor has already opened regulatory conversations in Europe and ****** an while its manufacturing facility in San Diego remains operational for a potential launch.
The financial picture moved the other direction. Cash and marketable securities fell to $237.9 million as of June 30, 2026, down from $318.1 million at the end of 2025. Second quarter net loss widened to $40.7 million, or $0.70 per share, compared to $25.9 million, or $0.57 per share, a year earlier, as operating expenses climbed to $42.9 million from $27.7 million. Research and development spending rose to $28.9 million and general and administrative costs jumped to $14.1 million from $5.7 million. The company booked zero revenue again.
Complicating matters, the left ventricular ejection fraction result across all patients was revised under the prespecified statistical model from a 2.4 percentage point difference at p=0.04 down to 1.8 percentage points at p=0.09, weakening a key secondary measure. An FDA Bioresearch Monitoring inspection in July produced a Form 483 with one observation. Non-Deramiocel pipeline work remains on hold, and the company's arbitration with NS Pharma over their distribution agreement isn't expected to begin until fall 2026.
#limb
Deramiocel's case still rests on real numbers. The HOPE-3 primary endpoint showed a statistically significant slowing of upper limb disease progression, with a 4.5% mean difference favoring the drug and a p-value of 0.029. During a separate advisory committee discussion, feedback on upper limb function was described as directionally supportive of that evidence. The cardiomyopathy subgroup's ejection fraction data held too, showing a 2.8 percentage point treatment difference at a p-value of 0.02, unchanged from the original ****** ysis.
Safety data spans more than 1,300 intravenous infusions across over 200 patients in three clinical trials, with more than 80 patients enrolled in open-label extension studies, some receiving infusions for over five years. The full HOPE-3 data set was published in The Lancet in July following independent peer review. The FDA has indicated it will review the coming BLA amendment and extend the PDUFA date accordingly, and Capricor has already opened regulatory conversations in Europe and ****** an while its manufacturing facility in San Diego remains operational for a potential launch.
The financial picture moved the other direction. Cash and marketable securities fell to $237.9 million as of June 30, 2026, down from $318.1 million at the end of 2025. Second quarter net loss widened to $40.7 million, or $0.70 per share, compared to $25.9 million, or $0.57 per share, a year earlier, as operating expenses climbed to $42.9 million from $27.7 million. Research and development spending rose to $28.9 million and general and administrative costs jumped to $14.1 million from $5.7 million. The company booked zero revenue again.
Complicating matters, the left ventricular ejection fraction result across all patients was revised under the prespecified statistical model from a 2.4 percentage point difference at p=0.04 down to 1.8 percentage points at p=0.09, weakening a key secondary measure. An FDA Bioresearch Monitoring inspection in July produced a Form 483 with one observation. Non-Deramiocel pipeline work remains on hold, and the company's arbitration with NS Pharma over their distribution agreement isn't expected to begin until fall 2026.
#limb
2 months ago
One of the most exciting players in the Juventus Next Gen team right now is Adin Licina, and he appears to be getting closer to breaking into Luciano Spalletti's first team. In recent times, players such as Kenan Yildiz and Fabio Miretti have progressed through the club's ranks and earned opportunities with the senior side, with more young players expected to follow.
Juventus have one of the best youth setups in Italian football, so the progression of young talents is not surprising. The Bianconeri have invested heavily in that area of the club, creating opportunities for promising players to develop and potentially reach the first team.
Licina and Yildiz are good friends, and both players arrived at Juventus after spells in the youth system of Bayern Munich. Licina has so far demonstrated that he could prove to be another impressive signing from the German club.
However, he could struggle to play regularly for Juventus' first team at this stage of his development, and Napoli are now showing interest in the midfielder. The Partenopei have been monitoring him closely since he moved to the Allianz Stadium this year and are working hard to convince him to join them.
(Photo by Jess Hornby/Getty Images)
#yildiz
Juventus have one of the best youth setups in Italian football, so the progression of young talents is not surprising. The Bianconeri have invested heavily in that area of the club, creating opportunities for promising players to develop and potentially reach the first team.
Licina and Yildiz are good friends, and both players arrived at Juventus after spells in the youth system of Bayern Munich. Licina has so far demonstrated that he could prove to be another impressive signing from the German club.
However, he could struggle to play regularly for Juventus' first team at this stage of his development, and Napoli are now showing interest in the midfielder. The Partenopei have been monitoring him closely since he moved to the Allianz Stadium this year and are working hard to convince him to join them.
(Photo by Jess Hornby/Getty Images)
#yildiz
2 months ago
When seen from the safe, comfortable vantage point of the living room sofa, it all seems so simple. Frank Mir was a UFC heavyweight champion with a long, decorated career in fight sports. His daughter Bella, being of his genetic lineage, also seemed to have some natural aptitude for the mixing of the martial arts, so it was only a matter of time until we saw her on the way to the UFC.
So when some people see her fighting on this Tuesday's edition of Dana White's Contender Series, they might think nothing of it. Pure logical progression, right? You'd think so, at least, if you've never spoken to a professional fighter about this very issue.
Many years ago I was having drinks with what you might call a mid-level UFC fighter whose wife had recently given birth to their first child. I offered my congratulations, like you do, and then without thinking much about it made an offhand remark about how maybe one day I'd cover one of his son's UFC fights the same way I'd covered the father's.
What I remember now is the look he gave me before he told me, in a tone of voice that said there was to be no joking on this subject, "That's honestly my worst nightmare."
Since I learn nothing, a couple years later I made the same mistake with former two-division UFC champion Jon Jones. Standing around the gym in Albuquerque, making conversation, I asked which of his daughters had the best chance of becoming a champion fighter some day.
#champion
So when some people see her fighting on this Tuesday's edition of Dana White's Contender Series, they might think nothing of it. Pure logical progression, right? You'd think so, at least, if you've never spoken to a professional fighter about this very issue.
Many years ago I was having drinks with what you might call a mid-level UFC fighter whose wife had recently given birth to their first child. I offered my congratulations, like you do, and then without thinking much about it made an offhand remark about how maybe one day I'd cover one of his son's UFC fights the same way I'd covered the father's.
What I remember now is the look he gave me before he told me, in a tone of voice that said there was to be no joking on this subject, "That's honestly my worst nightmare."
Since I learn nothing, a couple years later I made the same mistake with former two-division UFC champion Jon Jones. Standing around the gym in Albuquerque, making conversation, I asked which of his daughters had the best chance of becoming a champion fighter some day.
#champion
2 months ago
LeBron James, the newest star for the Philadelphia 76ers, gained plenty of attention when he launched a YouTube channel focused on golf in August. If that wasn't enough of an indication, James is apparently far more into the sport than expected. He continued to put his love of the sport on display Tuesday, when it was announced James had teamed up with the PGA Tour to bring a new golf event to his hometown.
The LeBron James Family Foundation Invitational will be played in Akron, Ohio, in 2027, per ESPN. The inaugural event will occur July 6 through July 7 and be played at the South Course at Firestone Country Club.
The event will be focused on helping kids see the benefits of golf. The LeBron James Family Foundation Invitational will feature "amateurs and pros from the tour's Pathway to Progression Pro-Bound Five program," per ESPN.
In a statement, James talked about the ways the sport can open doors and build relationships.
"Golf has become a passion of mine, and I've seen firsthand how the game can open doors, build relationships and create opportunities that many kids don't even know exist," James said in a statement. "This partnership with the PGA Tour gives my foundation a chance to introduce my I Promise students and more people to the game at a young age, support talented athletes chasing their dreams, and continue investing in the city of Akron that means everything to me."
#Event #family #akron
The LeBron James Family Foundation Invitational will be played in Akron, Ohio, in 2027, per ESPN. The inaugural event will occur July 6 through July 7 and be played at the South Course at Firestone Country Club.
The event will be focused on helping kids see the benefits of golf. The LeBron James Family Foundation Invitational will feature "amateurs and pros from the tour's Pathway to Progression Pro-Bound Five program," per ESPN.
In a statement, James talked about the ways the sport can open doors and build relationships.
"Golf has become a passion of mine, and I've seen firsthand how the game can open doors, build relationships and create opportunities that many kids don't even know exist," James said in a statement. "This partnership with the PGA Tour gives my foundation a chance to introduce my I Promise students and more people to the game at a young age, support talented athletes chasing their dreams, and continue investing in the city of Akron that means everything to me."
#Event #family #akron
2 months ago
LeBron James and the PGA Tour have teamed up to announce the LeBron James Family Foundation Invitational, a two-day event at Firestone Country Club for underrepresented aspiring golfers.
The experience will connect students in the LeBron James Family Foundation's I PROMISE program with professional golfers who advanced through the PGA Tour's Pathway to Progression Pro-Bound Five program.
The inaugural event is scheduled for July 6-7, 2027. Firestone Country Club recently hosted its final Kaulig Companies Championship, which is moving to Newport Beach, California. Firestone had a 72-year run of hosting a PGA Tour event, notably the Bridgestone Invitational that Tiger Woods dominated for much of the 2000s and 2010s.
"For many years, PGA Tour events at Firestone have been a staple of our community, benefitting our hometown and bringing people together," said Michele Campbell, executive director of the LeBron James Family Foundation. "With this event, we're excited to not only support more diverse golfers getting into the game, but to also expose our I PROMISE students and more youth in Akron to the world of possibilities that golf opens up."
James recently launched a YouTube channel as he brings people along his own golf journey. This new partnership is aimed at opening some doors to the game of golf that some might not have previously had to the same degree.
#james #firestone #golf
The experience will connect students in the LeBron James Family Foundation's I PROMISE program with professional golfers who advanced through the PGA Tour's Pathway to Progression Pro-Bound Five program.
The inaugural event is scheduled for July 6-7, 2027. Firestone Country Club recently hosted its final Kaulig Companies Championship, which is moving to Newport Beach, California. Firestone had a 72-year run of hosting a PGA Tour event, notably the Bridgestone Invitational that Tiger Woods dominated for much of the 2000s and 2010s.
"For many years, PGA Tour events at Firestone have been a staple of our community, benefitting our hometown and bringing people together," said Michele Campbell, executive director of the LeBron James Family Foundation. "With this event, we're excited to not only support more diverse golfers getting into the game, but to also expose our I PROMISE students and more youth in Akron to the world of possibilities that golf opens up."
James recently launched a YouTube channel as he brings people along his own golf journey. This new partnership is aimed at opening some doors to the game of golf that some might not have previously had to the same degree.
#james #firestone #golf
